Table 1.
Clinical characteristics of subgroups by non-COPD and COPD among never smoker NSCLC (n=345)
| Non-COPD (n=277) (n,%) | COPD (n=68) (n,%) | p-value | |
|---|---|---|---|
| Sex | <0.001 | ||
| Male | 54 (19.5) | 30 (44.1) | |
| Female | 223 (80.5) | 38 (55.9) | |
| Median age (year) | 64.2 (30–92) | 75.2 (48–89) | |
| Stage | 0.783 | ||
| I | 72 (26.1) | 15 (22.1) | |
| II | 23 (8.3) | 5 (7.4) | |
| III | 42 (15.2) | 9 (13.2) | |
| IV | 139 (50.4) | 39 (57.4) | |
| T stage T1/T2/T3/T4 | 68(31.2)/74(33.9)/25(11.5)/51(23.4) | 18(36.7)/13(26.5)/4(8.2)/14(28.6) | 0.594 |
| N stage N0/N1/N2/N3 | 91(41.6)/26(11.9)/44(20.1)/58(26.5) | 19(38.8)/3(6.1)/11(22.4)/16(32.7) | 0.581 |
| M stage M0/M1 | 135(50.4)/133(49.6) | 29(46.0)/34(54.0) | 0.535 |
| Median overall survival (months) | 29.8 (22.2–37.3) | 16.7 (11.2–22.2) | 0.002 |
| BMI (kg/m2) | 23.5±3.5 | 22.9±3.5 | 0.233 |
| EGFR mutation* | 129 (49.0) | 20 (30.3) | 0.006 |
| Number tested (%) | 263 (94.9) | 66 (97.1) | |
| ALK mutation* | 15 (6.2) | 3 (4.7) | 0.638 |
| Number tested (%) | 240 (86.6) | 64 (94.1) | |
| 1st line treatment | 0.038 | ||
| Surgery | 104 (37.7) | 16 (23.9) | |
| Chemotherapy | 94 (34.1) | 27 (40.3) | |
| Targeted therapy | 53 (19.2) | 10 (14.9) | |
| Radiotherapy alone | 3 (1.1) | 2 (3.0) | |
| Supportive care | 22 (8.0) | 12 (17.9) | |
| Undergone 2nd line treatment | 134 (48.4) | 24 (35.3) | 0.052 |
| ECOG | 0.007 | ||
| 0–1 | 244 (88.7) | 51 (76.1) | |
| ≥2 | 31 (11.3) | 16 (23.9) | |
| Pathology | 0.302 | ||
| Squamous | 12 (4.3) | 5 (7.4) | |
| Non-squamous | 265 (95.7) | 63 (92.6) | |
| FEV1 (liter) | 2.01±0.69 | 1.59±0.56 | <0.001 |
| FEV1 (% predicted) | 94.2±23.2 | 78.4±20.2 | <0.001 |
| FVC (liter) | 2.53±0.76 | 2.56±0.85 | 0.786 |
| FVC (% predicted) | 88.8±21.3 | 90.1±21.5 | 0.667 |
| FEV1/FVC (% predicted) |
78.7±6.9 | 62.5±8.0 | <0.001 |
| DLCO (abs) | 14.2±7.1 | 12.2±5.3 | 0.032 |
| DLCO (%) | 80.0±21.0 | 74.6±26.6 | 0.085 |
Notes: *The number in the brackets indicates a proportion of patients with positive mutation among the tested patients.
Abbreviations: ALK: anaplastic lymphoma kinase; BMI: body mass index; COPD: chronic obstructive pulmonary disease; DLCO: diffusing capacity of the lung for carbon monoxide; ECOG: Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor; FEV1; forced expiratory volume in 1 s; FVC: forced vital capacity; OS: overall survival.